Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals
Author – Anouk E Muller, Brenda C M De Winter, Birgit C P Koch
Journal Name – Journal of Antimicrobial Chemotherapy
Citation – Volume 79, Issue 5, May 2024, Pages 1093–1100
Ensuring robustness in the quality of antibiotic susceptibility test discs for four novel antibiotics
Author – Vinod K. Ahirrao, Rajiv A. Jadhav, Suyog N. Vaidya, Sachin S. Bhagwat, Ravindra D. Yeole, Mahesh V. Patel
Journal Name – Biomedical Chromatography
Citation – Volume 36, Issue 6, June 2022
Hg (OAc) 2/1, 2, 3-triazole-mediated efficient synthesis of Tazobactam
Author – Yasinalli Tamboli, Amit P Pund, Jaydeo T Kilbile, Arvind Y Merwade
Journal Name – Chemical Papers
Impact Factor – 2.14
Citation – AOP, 2022
Antimicrobial Activity of High-Dose Cefepime-tazobactam (WCK 4282) against a Large Collection of Gram-negative Organisms Collected Worldwide in 2018 and 2019
Author – Helio S.Sader, Cecilia G.Carvalhaes, Rodrigo E.Mendes, Mariana Castanheira
Journal Name – International Journal of Infectious Diseases
Impact Factor – 1.278
Citation – 2022, 116, 306-312
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria
Author – Shazad Mushtaq, Paolo Garello, Anna Vickers, Neil Woodford, David M Livermore
Journal Name – International Journal of Antimicrobial Agents
Impact Factor – 4.621
Citation – 2021, 57(5), May, 106318
In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine Lung Infection Model
Author – Maxwell J. Lasko, Kamilia Abdelraouf, David P. Nicolau
Journal Name – Antimicrobial Agents and Chemotherapy
Impact Factor – 4.904
Citation – 2021, 65(4), e02193-20
In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine-β-Lactamase-Producing Enterobacterales and Pseudomonas aeruginosa in the Neutropenic Murine thigh Infection Model
Author – Christian M Gill, Kamilia Abdelraouf, David P Nicolau
Journal Name – Journal of Antimicrobial Chemotherapy
Impact Factor – 5.439
Citation – 2021, 76(4), 993-1000
Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment
Author – Preston, Richard A.; Mamikonyan, Grigor; Mastim, Mushtaque; Garg, Dyal; Kemper, Christopher J.; Xu, Allan; Yeole, Ravindra; Chavan, Rajesh; Friedland, H. David; Bhatia, Ashima
Journal Name – Antimicrobial Agents and Chemotherapy
Impact Factor – 4.921
Citation – 2019, 63(10), e00873-19
Antimicrobial Susceptibility Testing Quality Control of β-lactam/ β-lactamase Inhibitor Combination Agents in Clinical Development
Author – Ayuen Lual, Heena Shah, Jane E. Ambler, Suyog Vaidya, Brian Beck
Journal Name – CLSI AST News Update
Citation – 2019, 4(1), 20-21
Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens
Author – David M Livermore, Shazad Mushtaq, Marina Warner, Simon J Turner, Neil Woodford
Journal Name – Journal of Antimicrobial Chemotherapy
Impact Factor – 5.113
Citation – 2018, 73(1), 126–133
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model
Author – Brian D. VanScoy, David Tenero, Simon Turner, David M. Livermore, Jennifer McCauley, Haley Conde, Sujata M. Bhavnani, Christopher M. Rubino, Paul G. Ambrose
Journal Name – Antimicrobial Agents and Chemotherapy
Impact Factor – 4.548
Citation – 2017, 61(12), e01052-17
Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a β-Lactamase Inhibitor and a Fourth-Generation Cephalosporin
Author – Stefan Riedel, Michael D Huband, Helio S Sader, Robert K Flamm, Ronald N Jones
Journal Name – Journal of Clinical Microbiology
Impact Factor – 4.054
Citation – 2017, 55(10), 3130-3134
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014
Author – Sader, Helio S.; Castanheira, Mariana; Mendes, Rodrigo E.; Flamm, Robert K.; Jones, Ronald N
Journal Name – Antimicrobial Agents and Chemotherapy
Impact Factor – 4.548
Citation – 2017, 61(4), e02409-16
Enhanced activity of cefepime-tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride
Author – Mariana Castanheira, Leonard R.Duncan, Paul R.Rhomberg, Helio S.Sader
Journal Name – Diagnostic Microbiology and Infectious Disease
Impact Factor – 2.341
Citation – 2017, 89(4), 305-309
Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model
Author – Maria J. Melchers, Anita C. van Mil, Claudia Lagarde, Jan den Hartigh, Johan W. Mouton
Journal Name – Antimicrobial Agents and Chemotherapy
Impact Factor – 4.548
Citation – 2017, 61(9), e00267-17